Valiant Organics Q1 FY27 Results (NSE: VALIANTORG)
Signal: Margins at cyclical peak
The read
The trajectory has materially inflected upward after Q3FY26's 8% OPM: consolidated EBITDA margin reached 19.4% from roughly 12% a year ago, supported by 73.4% EBITDA growth versus 13.3% revenue growth and a Pharma turnaround; however, raw-material intensity worsened by 360bps and the 254.3% PAT growth was amplified by ₹7.2299 Cr of associate profit.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹231.54 Cr | 13.3% | 6.3% |
| EBIT | ₹34.68 Cr | 110.3% | |
| Net profit | ₹29.05 Cr | 254.3% | |
| EPS | ₹10.44 | 256.3% | |
| EBIT margin | 19.4% |
P&L walk
Consolidated revenue increased to ₹231.54 Cr (+13.3% YoY), but raw-material cost rose to 64.9% of revenue from 61.4%, while EBITDA expanded 73.4% to ₹44.9 Cr and margin reached 19.4%; the operating recovery was amplified by Pharma's turnaround and ₹7.2299 Cr of associate profit.
Segments
Pharma was the main inflection: revenue rose to ₹55.8019 Cr (+3.8% YoY) but segment result turned positive at ₹16.8548 Cr from a ₹0.2064 Cr loss, while Specialty Chemicals revenue grew 16.6% to ₹175.7367 Cr and result grew 44.3% to ₹25.0553 Cr.
Key positives
- Consolidated EBITDA grew 73.4% to ₹44.9 Cr versus revenue growth of 13.3%, a 60.1pp growth gap, while EBITDA margin expanded 740bps to 19.4%.
- Employee cost grew 10.6% YoY and depreciation grew 8.5% while revenue grew 13.3%, demonstrating fixed-cost absorption behind the margin expansion.
- Pharma segment result turned positive at ₹16.8548 Cr from a ₹0.2064 Cr loss YoY, providing a new earnings contributor.
- Finance cost declined 15.2% YoY to ₹5.1293 Cr and EPS rose 256.3% to ₹10.44, broadly tracking PAT growth.
Key concerns
- Raw-material cost increased to 64.9% of revenue from 61.4% YoY, compressing gross margin by 360bps; the filing does not disclose the mitigation driver.
- Consolidated PAT of ₹29.05 Cr exceeded standalone PAT of ₹21.82 Cr by ₹7.23 Cr, making associate performance an increasingly material part of reported earnings.
- Revenue growth of 13.3% remains below the recent Q1FY26 growth rate of 21.4%, so the margin recovery is currently stronger than the top-line recovery.
Research and educational content only. Not investment advice.